Header Logo

Connection

Afaaf Liberty to HIV Infections

This is a "connection" page, showing publications Afaaf Liberty has written about HIV Infections.
Connection Strength

1,141
  1. Pharmacokinetics and safety of coformulated bictegravir, emtricitabine, and tenofovir alafenamide in children aged 2 years and older with virologically suppressed HIV: a phase 2/3, open-label, single-arm study. Lancet HIV. 2024 May; 11(5):e300-e308.
    View in: PubMed
    Score: 0,064
  2. Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial. Lancet Child Adolesc Health. 2023 10; 7(10):718-727.
    View in: PubMed
    Score: 0,061
  3. Microbiota in the oral cavity of school-age children with HIV who started antiretroviral therapy at young ages in South Africa. AIDS. 2023 08 01; 37(10):1583-1591.
    View in: PubMed
    Score: 0,060
  4. Experiences of South African caregivers disclosing to their children living with HIV: Qualitative investigations. PLoS One. 2022; 17(11):e0277202.
    View in: PubMed
    Score: 0,059
  5. Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial. Lancet HIV. 2022 09; 9(9):e638-e648.
    View in: PubMed
    Score: 0,058
  6. Optimizing the World Health Organization algorithm for HIV vertical transmission risk assessment by adding maternal self-reported antiretroviral therapy adherence. BMC Public Health. 2022 07 08; 22(1):1312.
    View in: PubMed
    Score: 0,057
  7. Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children. N Engl J Med. 2021 12 30; 385(27):2531-2543.
    View in: PubMed
    Score: 0,055
  8. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide in adolescents and children with HIV: week 48 results of a single-arm, open-label, multicentre, phase 2/3 trial. Lancet Child Adolesc Health. 2021 09; 5(9):642-651.
    View in: PubMed
    Score: 0,053
  9. Behavioral Functioning and Quality of Life in South African Children Living with HIV on Antiretroviral Therapy. J Pediatr. 2020 12; 227:308-313.e2.
    View in: PubMed
    Score: 0,050
  10. Abacavir Exposure in Children Cotreated for Tuberculosis with Rifampin and Superboosted Lopinavir-Ritonavir. Antimicrob Agents Chemother. 2020 04 21; 64(5).
    View in: PubMed
    Score: 0,049
  11. Negative Diagnostic PCR Tests in School-Aged, HIV-Infected Children on Antiretroviral Therapy Since Early Life in Johannesburg, South Africa. J Acquir Immune Defic Syndr. 2020 04 01; 83(4):381-389.
    View in: PubMed
    Score: 0,049
  12. Distinct epigenetic profiles in children with perinatally-acquired HIV on antiretroviral therapy. Sci Rep. 2019 07 19; 9(1):10495.
    View in: PubMed
    Score: 0,046
  13. Mitochondrial Impairment in Well-Suppressed Children with Perinatal HIV-Infection on Antiretroviral Therapy. AIDS Res Hum Retroviruses. 2020 01; 36(1):27-38.
    View in: PubMed
    Score: 0,046
  14. Educational delays among children living with perinatally-acquired HIV in Johannesburg, South Africa. AIDS Care. 2020 04; 32(4):438-444.
    View in: PubMed
    Score: 0,046
  15. A child with perinatal HIV infection and long-term sustained virological control following antiretroviral treatment cessation. Nat Commun. 2019 01 24; 10(1):412.
    View in: PubMed
    Score: 0,045
  16. Biomarkers of Aging in HIV-Infected Children on Suppressive Antiretroviral Therapy. J Acquir Immune Defic Syndr. 2018 08 15; 78(5):549-556.
    View in: PubMed
    Score: 0,043
  17. Safety and Efficacy of Atazanavir Powder and Ritonavir in HIV-1-Infected Infants and Children From 3 Months to <11 Years of Age: The PRINCE-2 Study. Pediatr Infect Dis J. 2018 06; 37(6):e149-e156.
    View in: PubMed
    Score: 0,043
  18. Patterns of Growth, Body Composition, and Lipid Profiles in a South African Cohort of Human Immunodeficiency Virus-Infected and Uninfected Children: A Cross-Sectional Study. J Pediatric Infect Dis Soc. 2018 May 15; 7(2):143-150.
    View in: PubMed
    Score: 0,043
  19. Childhood adversity increases the risk of onward transmission from perinatal HIV-infected adolescents and youth in South Africa. Child Abuse Negl. 2018 05; 79:98-106.
    View in: PubMed
    Score: 0,042
  20. A retrospective case-cohort study comparing treatment outcomes in abacavir versus stavudine containing first line antiretroviral treatment regimens in children <3yrs old, at a paediatric programme based in Soweto, South Africa. PLoS One. 2017; 12(7):e0180645.
    View in: PubMed
    Score: 0,040
  21. Extent of disclosure: what perinatally HIV-infected children have been told about their own HIV status. AIDS Care. 2017 03; 29(3):378-386.
    View in: PubMed
    Score: 0,038
  22. Early severe HIV disease precedes early antiretroviral therapy in infants: Are we too late? J Int AIDS Soc. 2014; 17:18914.
    View in: PubMed
    Score: 0,033
  23. Early time-limited antiretroviral therapy versus deferred therapy in South African infants infected with HIV: results from the children with HIV early antiretroviral (CHER) randomised trial. Lancet. 2013 Nov 09; 382(9904):1555-63.
    View in: PubMed
    Score: 0,031
  24. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature. 2012 Jul 25; 487(7408):482-5.
    View in: PubMed
    Score: 0,029
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.